Current therapeutic trends for tinnitus cure and control – a scoping review

Vatsal Chhaya MSc*¹, Divya Patel MPharm², Shamik Mehta MS(ENT)³,

Jignesh Rajvir MS(ENT)⁴ Vinodkumar Jhinjhuwadia MBBS ⁵, Pranshuta Sehgal

MS(ENT)⁶, Kapil Khambholja MPharm, PhD⁷

- 1. Senior Executive, Medical Writing and Real-World Evidence, Genpro Research Inc., Vadodara, Gujarat.
- 2. Trainee Medical Writer, Genpro Research Inc., Vadodara, Gujarat.
- 3. Consultant & ENT Surgeon, Ahmedabad, Gujarat.
- 4. Consultant & ENT surgeon, Gandhinagar, Gujarat
- 5. Consulting family physician, Rajkot, Gujarat.
- 6. Senior Resident (ENT), Hindu Rao Hospital, New Delhi.
- 7. Vice President, Genpro Research Inc., Boston, USA.

*Correspondence to:

Vatsal Chhaya

Senior Executive Medical Writing and RWE

Genpro Research Inc.

vatsal.chhaya@genproresearch.com

Abstract

Background: The inherent complexities of condition such as tinnitus with cause and mechanism not known, presents lack of high-level evidence to make an inference on the treatment approaches. A comprehensive review cannot be performed owing to insufficient number of trials. Hence a scoping review approach was adopted to provide a broad overview on approaches for tinnitus management.

Objective: To review the current evidence on prevalent treatment strategies used for tinnitus management and determine barriers and facilitators for adoption of treatment approaches in developed and developing countries.

Methods: The present scoping review was performed in compliance with PRISMA ScR checklist. Literature search was carried out in PubMed, Scopus, google scholar and Cochrane detabase particles published between 2010-2021 proprior in a therapeutic treatment strategies.

were included. However, therapies concentrating on symptomatic management were excluded.

Evidence with highest scientific hierarchy such as systematic reviews (SRs) and randomized-

controlled trials (RCTs) were considered. The context for the ScR was study-region based and

included studies from high-income and low and middle-income countries (HICs, LMICs)

Results: A total of 20 records were included with 11 SRs and 9 RCTs. Non-pharmacological

interventions demonstrated moderate efficacy, including transcranial magnetic- (TMS) and

direct current stimulation (tDCS), hearing aids (combined with sound generator or alone). No

specific drug found to have mode of action pertaining to target root cause due to lack of clinical

knowledge. Most of the trials used the same tools for tinnitus severity.

Conclusion: Although several scoping reviews are published with exclusive focus on

individual therapies, authors recommend umbrella review of systematic reviews to generate

evidence-based practice consensus for tinnitus.

Keywords: Tinnitus, management, developed and developing countries, scoping review.

Introduction

Clinical care pathway is a major deterministic factor for better patient outcomes. Conventionally, it is decided based on clinical acumen. However, with the increasing clinical inclination towards evidence-based medicine, best available evidence and patient values and preferences have been also strongly recommended to consider while determining treatment course. Nevertheless, there are a few clinical conditions with a blurry picture in terms of standard clinical care, including Tinnitus. Tinnitus is a clinical condition in which patients hear a ringing sound in their ears, impacting their quality of life. It may be referred as "phantom auditory perception" with variety of sounds including – hissing, buzzing, clicking, chirping, ringing, whistling, or cricket-like sound, which can be intermittent or continuous.

Tinnitus is not a disease but might be a composite manifestation of various otological, neurological and cardiovascular disorders², affecting an estimated 10-15% of adult population³. Epidemiologic data shows prevalence as 15% in USA⁴, 14.2% in Europe⁵, and similar in UK⁶, Asia⁷ and Africa⁸. It can be broadly classified as subjective and objective tinnitus. Subjective tinnitus, a more common type, refers to the perception of sound in absence of source or acoustic environment and can be perceived only by the patient. The rare type, objective tinnitus, refers to the sound produced by body and can be heard by the examiner too during the otologic examination. Other types include pulsatile, primary (idiopathic), secondary (underlying cause), acute (<6 months) or chronic (>6 months).

The condition can be distressing and debilitating and may have a negative impact on quality of life⁹. It may interfere with routine activities and can be bothersome. Individuals may experience anxiety, depression, irritability, sleep cycle disturbances, poor concentration, pain, and even suicidal thoughts in extreme cases. Along with personal and social impact, the economic impact

is huge. Global cost analysis estimated the cost to health sector range from \$67-107 billion, with 63-73% of global cost incurred to low- and middle-income countries (LMIC)¹⁰. The economic burden in UK is estimated to be £750 million per year¹¹.

Even-though the exact cause and mechanism for the condition is not known, it may be associated with age-related hearing loss, middle ear infection, trauma, head injury, loud work environment, anxiety, depression, or ototoxic drugs like NSAIDs (non-steroidal anti-inflammatory drugs), antibiotics, chemotherapeutic agents^{12–14}. The lack of proper mechanism makes it difficult to manage or treat the condition.

Despite several systematic reviews published on efficacy of several clinical interventions to cure the tinnitus, there is no food and drugs administration (FDA)approved, gold standard treatment or drug for tinnitus till date¹⁵. Several treatment pathways are identified through anecdotal evidence including but not limited to cognitive-behavioral therapy (CBT), tinnitus retraining therapy (TRT), biofeedback, psychoeducation or counselling, hearing aids, electrical stimulation, antidepressants, anticonvulsants, dietary supplements^{2,13,16–18}. While its implications in practice can be over debate, due to lack of high-level of evidence. In addition, combination therapies have shown promising potential not only in terms of relief from tinnitus-like distressing condition but also improvement in the holistic health of the patient^{19–21}.

Given such inconclusive inferences from the published systematic reviews (SRs) on efficacy/effectiveness of various clinical interventions, it is difficult to build the practice consensus despite of being highest on the evidence pyramid. Instead, a novel research concept has gained immense interest especially from policy perspective, known as "scoping review (ScR). It is a typical variant of the traditional systematic review, where rigorous specific attention towards any single interventions' efficacy and safety is replaced by collation of evidence in a comprehensive and informative manner. Although there are several scoping

reviews published on Tinnitus in the past, to the best of authors' knowledge, no research

provided holistic overview of the treatment options likely to be recommended in the actual

treatment of tinnitus except only one. Makar S et al. in 2017 described an overview of therapies

for the tinnitus; however, no information about its protocol registration was found. Also,

mapping of reported content in the same ScR with PRISMA-ScR checklist was not possible

due to the later release of revised checklist in 2020²².

The objective of present scoping review is to provide an update to the previously published

scoping review(s) on Tinnitus therapies as a whole with the complementary information. It also

discussed barriers and facilitators for the effective adoption of published treatment strategies

in the health system of developed and developing countries.

Material and Methods

Protocol registration

The protocol was registered in the open science framework registry (OSF), registration DOI:

10.17605/OSF.IO/R8D39

Study selection criteria

Study Design and Search Filters

Although being a scoping review, full-text systematic reviews and randomized controlled trials

in the English were included. The rationale behind such design restrictions was to consider

only the evidence with highest scientific hierarchy. Therefore, we excluded review articles,

case reports, case series, cross-sectional studies, and observational studies. Focusing on

recency of the data, records published before 2010 were not considered.

Population

Our target population for this scoping review included patients with any type of tinnitus. No

age or gender related restrictions were applied as per the protocol. The tinnitus was defined as

the sound in ears with or without any identifiable clinical cause. It included both subjective and

objective types, where the former refers to the tinnitus perceived only by the sufferer and the

later refers to the perception of tinnitus by both the examiner and sufferer through an objective

assessment of the condition.

Concept

We included the records containing information about the efficacy and safety endpoints of

pharmacological, phytomedicinal or non-pharmacological interventions for the treatment of

tinnitus. Studies including details about secondary outcomes like effect on tinnitus-induced

distress, anxiety or depression were also included. ScRs^{23–29} with focus on single intervention

or on habituation-oriented therapy (Tinnitus Retraining Therapy, Cognitive Behavioral

Therapies, etc.) were excluded to assess direct effect of the intervention unlike surrogate effect

in terms of habituation with the noise resulting from tinnitus or masking of the same. In other

words, studies assessing only effect of the intervention on improvement of quality of life from

symptomatic relief or habituation were excluded.

Context

We included studies from high-income countries and low and middle-income countries.

Search Strategy

Preliminary search was performed on PubMed to identify the relevant search terms used in

publications related to tinnitus. Following this step, a detailed search strategy was developed

which included three databases – Cochrane, PubMed, Scopus, and Google Scholar. Cochrane

search was performed using the string - "Tinnitus AND therap*" on the Cochrane website.

PubMed based search was performed using AI-powered tool named VOODY (Genpro

Research Inc.). The search strategy used for PubMed Search is as follows:

tinnitus[mh] OR tinnitus[tw] OR subjective tinnitus[tw] OR objective tinnitus[tw] OR pulsatile tinnitus[tw] OR primary tinnitus[tw] OR secondary tinnitus[tw] OR acute tinnitus[tw] OR chronic tinnitus[tw] OR chronic idiopathic tinnitus[tw] OR induced tinnitus[tw] OR drug induced tinnitus[tw] OR surgery induced tinnitus[tw] OR trauma induced tinnitus[tw] OR ringing buzzing*[tw] OR hearing

6

loss[tw]

AND

management[mh] OR therapeutics[mh] OR surg*[tw] OR surgical management[tw] OR non-surgical management[tw] OR pharmacolog*[tw] OR prevention and control [tw] OR treatment [tw] OR therap*[tw] OR drug therap*[tw] OR radiological therap*[tw] OR psycholog*[tw] OR psychotherap*[tw] OR sound therap*[tw] OR cognitive behavioral therap*[tw] OR tinnitus retraining [tw] OR retraining therap*[tw] OR cochlear implant*[tw] OR acoustic therap*[tw] OR cervical spine therap*[tw] OR orthodontic therap*[tw] OR auditory stimul*[tw] OR transcranial magnetic stimul*[tw] OR passive music therap*[tw] OR active music therap*[tw] OR physical therap*[tw] OR exercise therap*[tw] OR myofunctional therap*[tw] OR acupuncture[tw] OR mindfulness based intervention*[tw] OR masking therap*[tw] OR tinnitus masking [tw] OR hearing aid*[tw] OR counsel*[tw] OR quality of life [mh] OR health related quality of life [mh] OR QOL [tw] OR HRQOL[tw] OR health care[tw] OR quality of health care[tw] OR standard of care [tw] OR patient satisfaction [tw] OR disability adjusted life year* [tw] OR quality adjusted life year*[tw] OR DALY*[tw] OR QALY*[tw]

AND

epidemiology[mh] OR economic[mh] OR economic*[tw] developed countr*[tw] OR developing countr*[tw] OR high income countr*[tw] OR middle income countr*[tw] OR upper middle income countr*[tw] OR low middle income countr*[tw] OR India[tw] OR UK [tw] OR USA[tw] OR Europe[tw] OR Canada[tw]

Additionally, targeted search was performed from additional sources like Google, American Tinnitus Association, British Tinnitus Association, All Indian Institute of Speech and Hearing (AIISH). Also, an exclusive targeted search for tinnitus related scoping review was done using PubMed database to identify the published similar scoping reviews.

The whole study selection was performed by two independent reviewers. Any discrepancy regarding inclusion was resolved by mutual agreement or consenting third reviewer.

Data charting

The data charting instrument/template was prepared and piloted using three articles. Necessary fields and sub-sections based on research question framework (PCC) were added before commencing the extraction process. Two independent reviewers performed the charting. The extraction items included: author, year of publication, study type, type of tinnitus, population demographic details, concept (intervention used, outcome measures), context (study region). Outcome measures was sub-divided into primary (tinnitus severity, loudness, depression, anxiety) and secondary (QoL, HRQoL, depression, anxiety) outcomes. The extracted data was reviewed for its accuracy by second reviewer. Any disagreement was resolved by mutual

discussion or consensus from third reviewer. The charted data was presented using tabulation method.

Results

Study selection

An exhaustive literature search retrieved 4148 records from the following databases: PubMed (n =838), Scopus (n = 2441), Cochrane (n = 538), Google Scholar (n = 331). 754 records were removed during deduplication. Out of 3394 records screened, 3124 records were excluded based on non-relevance. Finally, 86 full text records were screened, out of which 20 records were included for qualitative synthesis. Adaptation was made in the original template of PRISMA-ScR flow diagram³⁰ as we considered web content from websites of World Health Organization and American Tinnitus Association only as a supplementary data with no stringent eligibility criteria applicable. A detailed description of study selection process is shown in Fig.1 (PRISMA flow diagram).

Report characteristics

Of the 20 included records, 11 were systematic reviews and 9 were RCTs. 6/9 RCTs were double-blinded, 5/6 RCTs intervening stimulation techniques were sham (inactive stimulation) controlled and 1 study was placebo-controlled (intervening drug AM-101). Study-region based findings suggested 2 records from United States of America (USA), 10 from Europe (Netherlands, United Kingdom (UK), Italy), 2 from Germany and Brazil, 1 from Middle east, and 1 multisite study (North America, Europe, Asia). Sample-size difference was present in the included studies, ranging from 20 participants to 343 participants with respect to RCTs, whereas systematic reviews included a highest of 1199 participants. Population in the included studies were \geq 18 years age. Gender-based criteria was not mentioned in all included studies; however, 4 studies determined male:female ratio and found higher proportion of male (75.5%) compared to female (24.5%)^{31–34}.

Study characteristics

Population

The review did not exclude records based on tinnitus type. Hence, various types of tinnitus were identified including chronic (n=559), acute (n=343), subjective (n=209), chronic-subjective (n=30), subjective-idiopathic (n=590), chronic bilateral (n=21), acute inner-ear (n=248), chronic subjective unilateral/bilateral non-pulsatile primary tinnitus (n=53).

Concept

Tinnitus Severity Measurement Tools

Majority of the studies used Tinnitus Handicap Inventory (THI)^{32,34–41}, Tinnitus Handicap Questionnaire (THQ)^{34,40,42,43}. Other tools used for assessment of tinnitus outcome included Tinnitus Functional Index (TFI)^{31,36}, Visual-Analog Scale (VAS)^{36,38,44}, Beck Depression Inventory (BDI)^{34,40,41}, Tinnitus Reaction Questionnaire (TRQ)^{34,40}, Clinical Global Impression (CGI)³⁸, Tinnitus Severity Index (TSI)^{41,45}. One study each used Pittsburgh Sleep Quality Index (PSQI)⁴¹ to assess sleep disturbance and Hamilton Depression Rating Scale (HDRS)⁴⁰ to assess depression. ^{22,24–31}, THQ^{34,40,42,43}. Other tools used for assessment of tinnitus outcome includes TFI^{31,36}, VAS^{36,38,44}, BDI^{34,40,41}, TRQ^{34,40}, CGI³⁸, TSI^{41,45}. One study each used PSQI⁴¹ to assess sleep disturbance and HDRS⁴⁰ to assess depression.

Interventions

The interventions included three major categories: pharmacological (n = 2), complementary and alternative medicine (CAM) (n = 8) and non-pharmacological interventions (n = 10). Pharmacological and CAM interventions included AM-101 (NMDA receptor antagonist)^{33,46}, zinc³⁷, ginkgo biloba (GB) extract⁴⁷, melatonin⁴¹, anti-depressant⁴², and anti-convulsant⁴³. Whereas non-pharmacological interventions included transcranial magnetic stimulation (TMS)^{31,34,36,45}, vagus nerve stimulation (VNS)³², transcranial direct stimulation (tDCS)^{38,44,48}, devices such as hearing aid^{35,39} (alone or in combination with sound generator).

Outcomes

Outcomes were further sub-divided to primary and secondary outcomes. **Table 1** presents the charted data for this project. Only 3 studies assessed secondary outcomes including depression, anxiety, and level of sleep disturbance.

Table 1: Data charting table - tinnitus management

				POPUL ATION					CO	ONCEPT			CONTEXT
Sr · N	Author	Publicati on year	Evidenc e type	Populat ion	Type of tinnitus	Study perio d		Intervention		Outo	comes	Remarks	Study region
0.							Non- pharmacologic al	pharmacologic al	Complementary and alternative medicine	Primary outcome	Secondary outcome		
1	Sereda et al. ³⁵	2018	Systema tic Review	n = 590 age = ≥18 y	acute or chronic subjective idiopathic tinnitus	-	Devices used: Hearing aid(HA), South Generator(SG), Combination(C D) device(amplific ation and sound generation in a single device); placebo; education only Tool used for Severity Check : Tinnitus Handicapped Index(THI)	NIL	NIL	Effect on Tinnitus Severity Index HA vs. SG - No difference CD vs HA - no difference between them (standardised mean difference - 0.15, 95% confidence interval -0.52 to 0.22; No safety outcomes assessed in any of included studies;	Not assessed (Depression, Anxiety, Quality of life [QoL], Health related QoL, tinnitus intrusiveness, ability to ignore, concentration, quality of sleep and sense of control)	No recommendatio ns made on superiority and inferiority of any of the intervention over the others due to low quality of evidence	Europe
2	Yuan et al. ⁴⁸	2018	Systema tic Review	-	-	-	Stimulation: Transcranial Direct Current Stimulation(tDC S) current intensity: 1-2 mA, session: single or repeated for 15- 20 min	NIL	NIL	Effect on tinnitus distress and loudness: moderate to significant reduction (applied at dorso-lateral prefrontal cortex [DLPFC] and auditory cortex [AC] region) Effect on tinnitus related depression and anxiety: Improved when	-	Given the heterogeneity of studies, tCDS can be recommended as an adjunct/comple mentary therapy for nontractable tinnitus	

										applied to bifrontal region			
3	Londero et al. ³⁶	2018	Systema tic Review	-	Subjective tinnitus	-	Stimulation: repetitive transcranial magnetic stimulation (rTMS) Session:1000- 2000 per session. Frequency: 1Hz Tools used: THI, TFI (Tinnitus functional Index), VAS (Visual Analog Scale)	NIL	NIL	Effect on tinnitus severity: rTMS on left temporo-parietal junction may have short-term effects	-	Partial or temporary benefit on low frequency rTMS Limitation: small sample size, divergent population	Europe
4	Formane k et al. ³⁴	2018	RCT (sham controll ed, double- blinded)	n = 53. M:62% F:38%	chronic subjective unilateral or bilateral nonpulsati le primary tinnitus	-	Stimulation: rTMS; rTMS, sham, Session: 2300 pulses per session Frequency: 25Hz (DPFLC) & 1Hz (AC) Follow-up: 1 and 6 months after last session Tools used: THI, THQ (Tinnitus Handicap Questionnaire),	NIL	medicament therapy: gingko biloba extract	Effect on THI score: Improvement in 63% (rTMS), 58% (sham group), and 28% (medicament group) after 1 month, however clinically irrelevant. Effect on THQ, BDI, TRQ: non- significant improvement Safety outcome: Temporal side- effects observed in 3 patients each from	-	-	Europe

							BDI (Beck Depression Inventory), TRQ (Tinnitus Reaction Questionnaire)			rTMS and sham stimulation group.			
5	Staecker et al. ³³	2017	RCT (double-	n = 343 M:77%	acute tinnitus	84 days	NIL	Drug: AM-101	NIL	Effect on hearing threshold:	-	-	North America,
			blinded,	F:23%		-				transient increase in			Europe, Asia
			multisit	Age =						< 7% patients			
			e)	≥18 y						Safety outcome:			
										mild AE in 4-6%			
										patients (ear pain,			
										discomfort)			
										Repeated dose can			
										be used for 3 to 5			
										days for acute			
	T. 1	2017	D.CIT	20		0.4	G. 1) III	NIII.	tinnitus		000/	110.4
6	Tyler at al. ³²	2017	RCT	n = 30	chronic	84	Stimulation:	NIL	NIL	Effect on tinnitus	-	90%	USA
	a1.52		(double-	M:83%	sensorineu	days	VNS (Vagus			severity: >20%		participants kept	
			blinded)	F:17%	ral tinnitus		Nerve			improvement in		the device and rest had the	
							Stimulation); VNS paired			50% participant		device	
							with tone,			(VNS paired) after 42 days (p=0.0012)		explanted	
							unpaired VNS			improvement in		explained	
							Tools used:			56% participants			

7	Zenner et al. ⁴⁹	2017	Systema tic Review	-	chronic idiopathic tinnitus	-	Multidisciplinar y treatment	-	-	strong recommendation for tinnitus-specific cognitive behavioral therapy (CBT) pharmacological therapy, if	Effect on QoL, tinnitus distress and depression: validated structured tinnitus-specific CBT along with counseling found effective	-	Germany
										necessary for depression Insufficient evidence for recommendation of TMS or tDCS			
8	Person et al. ³⁷	2016	Systema tic Review	n = 209 Age = ≥18y	Subjective tinnitus	-	NIL	NIL	Drug: zinc; placebo Included studies criteria: RCT Tools: non- validated instrument (2trials), THI (1trial)	Effect on tinnitus severity and disability: No overall effect Safety outcome: mild adverse effects in 2/3 studies	Not assessed (QoL, depression, anxiety, psychoacoustic parameters)	-	Brazil
9	Forogh et al. ³⁸	2015	RCT (sham controll ed, double- blinded)	n = 22 Age = ≥18y	chronic tinnitus	14 days	Stimulation: tDCS; anodal, cathodal, sham Current intensity: 2 mA Duration: 20 min Follow-up period: 14 days after last session Tools used: THI, VAS, CGI (Clinical Global Impression)	NIL	NIL	Effect on tinnitus loudness and distress: Reduction in 3 patients (anodal tDCS) and 2 patients (sham) at 14 days follow-up. VAS scores reduction: not significant for both the groups Safety outcomes: worsening of symptoms in 36.4% patients	-	Significant long-term effects were not found; however, it was able to induce neuromodulatio n	Middle East

10	Miroddi	2015	Systema	n = 356	I _	_	NIL	NIL	Drug: melatonin;	Effect on tinnitus	_	_	Europe
10	et al. ⁴¹	2013	tic	11 = 330			TVIL	IVIL	melatonin alone,	severity: canot be	_		Lurope
	et ar.		Review						combined sulpiride,	inferenced due to			
			Review						combined	methodological			
									sulodexide Dose:	weakness			
									3mg daily p.o.	Effect on sleep			
									Tools used: THI,	disturbance:			
									PSQI (Pittsburgh	melatonin alone			
									sleep quality index),	improved sleep			
									TSI, BDI	distubance			
11	Folmer et	2015	RCT	n = 64	chronic	182	Stimulation:	NIL	NIL	Effect on tinnitus	-	_	Europe
	al. ³¹		(sham	M:80%	tinnitus	days	rTMS; active			severity: significant			
			controll	F:20%			rTMS, sham			reduction in TFI			
			ed)				Session: 2000			(active rTMS) at 26			
			,				pulses per			weeks (effect size =			
							session for 10			0.92			
							days			p=0.007 when			
							Frequency: 1			compared to			
							Hz			placebo group.			
							Follow-up:						
							1,2,4,13, and 26						
							weeks after last						
							session						
							Tools used: TFI						
12	Heyning	2014	RCT	n = 248	acute	90	NIL	Drug : AM-101		Effect on	-	Repeated i.t	Europe
	et al.46		(placebo	Age 18-	inner-ear	days		Dose: low dose-		minimum masking		injections of	
			-	65 y	tinnitus			0.27 mg/ml,		level (MML): No		AM-101 are	
			controll					high dose- 0.81		significant change		safe and well-	
			ed,					mg/ml; or		Effect on tinnitus		tolerated	
			double-					placebo		loudness,			
			blinded)					Duration: 3-		annoyance and			
								consecutive		sleep difficulties:			
								days		significant			
								Assessment:		improvement in			
								Day 0,1,2,7,30		high-dose group			
								and 90		(p<0.001)			
										Safety outcomes: 7			
										patients reported			
										adverse effects (3-			
										study drug group, 4-			
										placebo)			

13	Dos santos et al. ³⁹	2014	RCT (blinded)	n = 49	-	-	Devices used: HA, Combined device (HA + SG) Usage criteria: minimum 8 hours a day Timeperiod for assessment: after 3 months of device usage Tools used: THI	NIL	NIL	Effect on tinnitus annoyance: Reduction in 62.5% patients (CD) and 78% patients (HA group) however not significant p=0.24	_	Superiority over using CD and HA was not found	Brazil
14	Baldo et al. ⁴²	2012	Systema tic Review	n = 610	-	-	NIL	Drug: Anti- depressants Included studies criteria: Randomised placebo- controlled. trials Tools used for tinnitus severity: Tinnitus Handicapped Questionnaire (THQ) Tools used for depressive symptoms: HDRS (Hamilton Depression Rating Scale)	NIL	Effect on tinnitus severity and disability: No significant changes Effect on depressive symptoms: Nor- triptyline showed to reduce depression. Other studies showed non- significant change/not assessed. Safety outcomes: common side- effects observed such as dry mouth, sexual dysfumction, sedation	Quality of life (QoL): Improved QoL reported for trazodone(atypical anti-depressant), however not significant	The beneficial effect were reported from single trials. Pooled data shows non- significant changes or no effects	-
15	Hoare et al. ⁵⁰	2011	Systema tic Review	-	-	-	multidisciplinar y treatment. Included studies criteria: RCTs using validated questionnaires Tools used:		-	Non- pharmacological intervention: significant improvement through CBT (TRQ, TQ) (specifically therapist-delivered	-	No RCTs found for hearing aids, counseling and sleep management.	Europe

							TRQ, TQ, THI, BDI, THQ, HDRS			CBT). Pharmacological intervention: only antidepressants class of drugs showed evidence for potential benefit (THQ, HDRS)			
16	Boettiche r ⁴⁷	2011	Systema tic Review	n = 1199			NIL	NIL	Drug: Ginkgo biloba extract Included studies criteria: Randomised placebo-controlled, double-blinded	Effect on tinnitus severity: Not all but trials investigating EGb 761 showed significant improvement, found superior to placebo	-	Efficacy of other ginkgo preparations cannot be proven (might be attributable to methodological bias)	Germany
17	Hoekstra et al. ⁴³	2011	Systema tic Review	n = 453	chronic tinnitus	-	NIL	Drug: Anti- convulsants Included studies criteria: RCT placebo- controlled Tools used: THQ, TQ, THI, TEQ (Tinnitus Effects Questionnaire)	NIL	Effect on tinnitus severity: non- significant improvement (lamotrigine, flunarizine, carbamazepine) Safety outcome: 18% pariticipants experienced side effects (nausea, dizziness headache)	Effect on tinnitus- specific health- related quality of life: No effect	-	Europe
18	Menneme ier et al. ⁴⁵	2011	RCT (sham- controll ed, crossov er)	n = 21. Age: 28-75 y	chronic bilateral tinnitus	7 days	Stimulation: rTMS; active, sham Frequency: 1Hz. Duration: 30 minutes session for 5 days Tools used: THQ, TSI	NIL	NIL	Effect on tinnitus loudness: 43% patients (active rTMS) reduced tinnitus loudness. However, the same not reflected in PET activity	-	PET scans did not support the hypothesis that rTMS at 1Hz reduces neural acitivity at the stimulation site to improve tinnitus	USA

19	Garin et	2011	RCT	n = 20	chronic	42	Stimulation:	NIL	NIL	Effect on tinnitus	-	_	Europe
	al. ⁴⁴		(sham	Age =	tinnitus	days	tDCS; anodal,			intensity:			
			controll	18-80 y			cathodal, sham			improvement in			
			ed,				Intensity: 1mA			35% patients			
			double-				Duration: 20			(anodal tDCS).			
			blinded)				min			Non-significant			
			,				Session: 3			changes through			
							session after 2			cathodal tDCS			
							weeks interval			Effect on			
							Tools used:			depression and			
							VAS, TQ			anxiety: No			
							(Tinnitus			significant			
							Questionnaire),			difference (TQ,			
							BDI			BDI)			
20	Fornaro	2010	Systema	-	Subjective	-	NIL	Drug:	NIL	Nortyptiline	-	-	Europe
	and		tic		tinnitus			Psychopharmac		(tricyclic anti-			
	Martino ⁵¹		Review					ological agents		depressant) and			
										sertraline (serotonin			
										and nor-epinephrine			
										reuptake inhibitor)			
										were found superior			
										to placebo. Majority			
										sedative-hypnotics			
										class of drugs were			
										found effective and			
										superior to placebo.			
										Whereas			
										antipsychotics were			
										found partially			
										effective			

Non-pharmacological interventions

Transcranial direct stimulation (tDCS)

3 studies (2 RCT, 1 SR) assessed chronic tinnitus using tDCS ^{38,44,48}. The effects of tDCS were inclined towards anodal tDCS, whereas cathodal tDCS resulted in non-significant changes. Systematic review by Yuan et al. 48 included studies performing single or repeated session of tDCS at current intensity of 1-2 mA. Similar outcome measured by Forogh et al.³⁸, determined reduction (anodal tDCS); however, not significant. There was a moderate to significant reduction in tinnitus distress and loudness when applied to dorso-lateral prefrontal cortex (DLPFC) and auditory cortex (AC) region. The study also found reduction in tinnitus-related depression and anxiety specific to bifrontal cortex. Although, RCT by Garin et al.⁴⁴ did not found such effect. Inference could not be constructed based on methodological issues including sample size and study period. Further, assessing safety outcomes, 36.4% patients had symptoms worsened as measured by one study³⁸. ^{28,34,38}. The effects of tDCS were inclined towards anodal tDCS, whereas cathodal tDCS resulted in non-significant changes. Systematic review by Yuan et al.⁴⁸ included studies performing single or repeated session of tDCS at current intensity of 1-2 mA. Similar outcome measured by Forogh et al.³⁸, determined reduction (anodal tDCS); however, not significant. There was a moderate to significant reduction in tinnitus distress and loudness when applied to dorso-lateral prefrontal cortex (DLPFC) and auditory cortex (AC) region. The study also found reduction in tinnitus-related depression and anxiety specific to bifrontal cortex. Although, RCT by Garin et al.⁴⁴ did not found such effect. However, inference could not be constructed based on methodological issues including sample size and study period. Further, assessing safety outcomes, 36.4% patients had symptoms worsened as measured by one study³⁸.

Repetitive transcranial magnetic stimulation (rTMS)

4 studies intervened patients with chronic and subjective tinnitus using rTMS^{31,34,36,45}. The studies used 1000-2300 pulses per session at frequency of 1 Hz. The studies found reduction in tinnitus severity³¹ and loudness⁴⁵. Nevertheless, inference could not be made, subjected to difference in sample size and study follow-up period. Formanek et al.³⁴ compared rTMS, sham stimulation and ginkgo biloba extract. THI score improved in all the groups; however, superiority cannot be obtained. With regard to safety outcome, temporal side-effects were observed in rTMS and sham stimulation group. Mennemeier et al.⁴⁵ performed rTMS on tinnitus patients and correlated with PET scans. Although THQ and TSI shown improvement in tinnitus loudness, PET scans failed to reflect the same.

Vagus nerve stimulation (VNS)

Only one study³² intervened using VNS in patients with chronic sensorineural tinnitus, comparing VNS paired and unpaired with tones. 50% participant shown improvement in tinnitus severity after 42 days which increased to 56% after 84 days in VNS paired group.

Hearing-aids (HA)

HA were used in two studies and compared with combined (CD) device (HA and sound generator). The studies did not found difference in tinnitus severity and annoyance improvement among HA and CD as measured by THI.

Pharmacological interventions

Anti-depressants

Baldo et al.⁴² performed an SR on anti-depressant (nor-triptyline, a tricyclic anti-depressant) use in tinnitus. The findings suggest reduced tinnitus-specific depressive symptoms and improved QoL (trazodone, atypical anti-depressant). The findings were from single trials and pooled analysis described non-significant effect. Hence inference could not be made.

Anti-convulsants

A SR carried out by Hoekstra et al.⁴³ assessed effect of anti-convulsants (lamotrigine, carbamazepine, flunarizine). The study determined improvement in tinnitus severity measured

by THQ, THI, Tinnitus questionnaire (TQ) scales; however, not significant. The study also

failed to show beneficial effect on HRQoL.³³ assessed effect of anti-convulsants (lamotrigine,

carbamazepine, flunarizine). The study determined improvement in tinnitus severity measured

by THQ, TQ, THI, TEQ scales; however, not significant. The study also failed to show

beneficial effect on HRQoL.

NMDA receptor antagonists

AM-101 is a NMDA(N-methyl-D-aspartate) receptor antagonist. A multi-site RCT described

increase in hearing threshold in <7% patients³³. Another study by Heyning et al.⁵² carried out

dose-dependent study. There was a significant improvement in tinnitus loudness, sleep

disturbance in high-dose (0.81mg/ml) group. However similar effect was not observed in

minimum masking level (MML). Mild adverse effects were observed. The studies suggest

repeated dose of AM-101 to be safe and well-tolerated.

Complementary and Alternative Medicine

Ginkgo Biloba Extract (GB)

The findings from SR performed to evaluate effects of GB extract in tinnitus patients was

suggestive of reduced tinnitus severity, though the effect was observed to specific EGb 761

extract and no other extracts of GB⁴⁷. No significant differences were found comparing rTMS,

sham and GB extract³⁴.

Zinc supplementation

Effects of oral zinc supplement was evaluated in patients with subjective tinnitus³⁷. However,

the study failed to conclude improvement in tinnitus symptoms due to lack of evidence. 2 out

of 3 studies included in SR described mild adverse effects.

Melatonin

One study reviewed the effects of melatonin at dose of 3mg when used alone and in

combination with sulpiride or sulodexide⁴¹. The review was unable to demonstrate effect on

21

tinnitus severity; however, melatonin alone improved sleep disturbance.

Our study included two SRs assessing multidisciplinary treatment options^{40,49}. The studies showed significant improvement and recommended cognitive-behavioural therapy (CBT) along with counselling. With regards to pharmacological intervention, only anti-depressant showed potential for beneficial effect.

Discussion

Owing to inherent complexity of the clinical condition for the patients with tinnitus and failure to identify and correlate the root cause and associated mechanism, sufficient number of trials have not been possible to conduct in case of the tinnitus. To overcome these challenges, first step was proposed to enlist the possible interventions, scales used, and outcomes assessed for tinnitus to identify research lacunae if any. This was accomplished by the recommended evidence synthesis method - Scoping review. Being an update, this scoping review did not consider already published information but presented complementary information to provide a clear picture about all possible therapies while determining the holistic care pathway for the tinnitus. Also, broad spectrum of information covering both HICs and LMICs introduced comprehensiveness in data charting process. However, recency of the information was ensured through limiting studies between timeframe 2010-2021 (from last 10 years). This also helped to understand current vistas in the therapeutic management of the tinnitus as well as the directions for tinnitus research progress.

The review included only systematic reviews (11) and RCTs (9), contributing to highest level of evidence strength. 8 out of 20 studies included in this scoping review intervened using stimulation technique (TMS, tDCS, and VNS). Overall, the stimulation showed reduction in tinnitus severity and perception. Although, the effects were dependent of the region of application and the polarity (anodal/cathodal). Yuan et al.³⁹ determined moderate to significant reduction in tinnitus loudness, distress and tinnitus-related depression and anxiety when tDCS

was applied to DLPFC and auditory cortex AC region. The reason behind the inclination of findings towards DLPFC and AC might be the involvement of frontal region in pathophysiology of tinnitus^{42,43}. Both rTMS and tDCS reduces the abnormal neuronal hyperactivity^{44,45} and modulates tinnitus transiently; however, long-term effects were not observed⁴⁶. Moreover, tDCS demonstrated clinical and cost-effectiveness⁴⁷.

HA amplification reduces tinnitus perception and help in coping, and masks the tinnitus using amplified sound. CD are relatively new approach and have shown to reduce tinnitus severity^{26,30}. However, superiority was not established among HA and CD. Nevertheless, recent advancement pertaining to use of artificial intelligence techniques, acoustic sensors have been developed to analyze the surrounding environment, reduce noise, and adjust the sound based on hearing preferences. Consensus-based guidelines recommend use of HA for persistent and bothersome tinnitus, and often considered as first-line treatment^{48–50}.

On the other side, there was questionable efficacy of pharmacological interventions to treat or cure tinnitus. Nevertheless, therapies oriented to achieve surrogate effect through addressing complex comorbidities aligned in patients with tinnitus such as depression, anxiety, insomnia was evident. For example, anti-depressants have potential for reduction in tinnitus-specific depression^{31,33,51}. Novel approaches including AM-101 (NMDA receptor antagonist), anti-convulsant, zinc, ginkgo biloba and more, have shown to be effective in reducing tinnitus severity. Contradictory outcomes were determined from two trials which assessed efficacy of AM-101^{24,37}. However, the studies indicate the intervention to be safe and well-tolerated for repeated doses. Besides, the study determined majority of RCTs (7/9) were performed in HICs, indicating need of the hour for comparative effectiveness research for the tinnitus care solutions using empirical treatments in case of LMICs.^{25,29}.

A similar scoping review by Makar et al.²¹ described the interventions with surrogate effect on tinnitus, including counselling, tinnitus masking, tinnitus retraining therapy (TRT), cognitive behavioral therapy (CBT), relaxation, and attention diversion in tinnitus patients. Complementing to the same, our study described role of non-pharmacological as well as adjuvant pharmacological treatment modalities which may play little to moderate role in tinnitus management. Unlike previous scoping review(s) which either focused on interventions with surrogate effect or specific to individual interventions, we understand our study demonstrated uniqueness with enlisting the details of interventions with highest quality of supporting evidence. In addition, our scoping review data charting included every detail about study interventions, severity scales, outcomes, and recommendations. Thus, it helped better understand methodological quality of the included records. Albeit it is to be noted that scoping review does not emphasize on critical appraisal of collected evidence, it is useful to chart information in comprehensive manner to guide the further research. For example, although it was not primary aim to assess the effect on QoL or HR-QoL, we included the variables considered for assessing secondary objective i.e., effect of OoL in relation with the tinnitus. Other scoping reviews have been performed on individual therapies such as psychotherapy⁵², hearing aids⁵³, amplification technique⁵⁴, tDCS⁵⁵. However, failed to make recommendation due to lack of quality evidence.²⁰

Limitation

Despite a well-devised search strategy, the study could not demonstrate any actionable insights based on collected evidence. This could be partially attributable to limited access to subscription journals and study search restricted for only full-text free articles. Also, we were not able to demonstrate the charted data in an easily interpretable form due to time constraints. We did not obtain any substantial information from the web-portals of associations despite their mention as a potential source of information. Lastly, we acknowledge several significant

changes to the registered protocol version on OSF platform, which were deemed mandatory to be implemented during the course of project execution. This included 1) Removal of objective to assess health systems related barriers and facilitators due to lack of relevant secondary data and its out-of-scope nature 2) The study team included 3 investigators; however, additional research team members including ENT specialists and a family physician was introduced to the team to expedite the manuscript authoring work and for the quality improvement purposes and 3) Inconsistencies were found between the source of information mentioned in methods section and eligibility criteria in appendix. As the resolution, eligibility criteria were approved in its original form without any relaxation regarding the information source type (textual note, non-scientific record).

Futuristic Implications for Research and Practice

Continual advancements are taking place in the field, be it novel devices, implant system⁵⁶ or surgery. Although there is no surgical treatment to cure tinnitus, neuromodulation of trigeminal nerve seems promising approach and requires further investigations in future⁵⁷. Deep brain stimulation technique has been used for Parkinson, psychiatric conditions showing tinnitus relief as a beneficiary effect⁵⁸. Clinical trials investigating DBS in tinnitus patients is recommended with intensification of current level of scientific rigor. Also, the curative potential of brain surface implants needs a serious attention of researchers working in the area of experimental therapies for tinnitus.

Given the inconclusive evidence with poor strength to advocate any specific treatment option or combination of a few, it is difficult to generate the practice consensus with high degree of generalizability. However, as a next step, along with ongoing research and development initiatives, umbrella review – review of systematic reviews - could be recommended with exclusive focus on the published systematic reviews. Moreover, the interventions with

moderate effect must be studied in larger group of patients with robust RCT designs with minimal bias and validated questionnaires.

Conclusion

The present scoping review charted complementary evidence about the effect of various non-pharmacological and pharmacological interventions being used for tinnitus, which were different than those published in previous scoping review within Indian context. Moderate improvement has been shown for r-TMS and t-DCS, warranting large-scale research to further investigate region-specific and intensity level-specific dependency of the effect of respective interventions. The stimulation presented partial effect and long-term effect was not established. To summarize, complexity of tinnitus and inconclusive strength of the available research evidence demands intensification of translational research and encouragement of rigorous knowledge dissemination for the development of practice consensus on tinnitus in the near future.

References:

- Jastreboff PJ. Phantom auditory perception (tinnitus): mechanisms of generation and perception. *Neuroscience Research*. 1990;8(4):221-254. doi: https://doi.org/10.1016/0168-0102(90)90031-9
- 2. Tang D, Li H, Chen L. Advances in Understanding, Diagnosis, and Treatment of Tinnitus. Advances in experimental medicine and biology. 2019; 1130:109-128. doi:10.1007/978-981-13-6123-4 7
- 3. Henry JA, Reavis KM, Griest SE, et al. Tinnitus: An Epidemiologic Perspective. *Otolaryngologic Clinics of North America*. 2020;53(4):481-499. doi: 10.1016/j.otc.2020.03.002
- 4. Understanding the Facts | American Tinnitus Association. Accessed May 4, 2021. https://www.ata.org/understanding-facts#nhnes
- 5. Axelsson A, Ringdahl A. Tinnitus--a study of its prevalence and characteristics. *British journal of audiology*. 1989;23(1):53-62. doi:10.3109/03005368909077819
- 6. The number of people living with tinnitus in the UK higher than previously thought British Society of Audiology. Accessed May 4, 2021. https://www.thebsa.org.uk/the-number-of-people-living-with-tinnitus-in-the-uk-higher-than-previously-thought/

- 7. Xu X, Bu X, Zhou L, Xing G, Liu C, Wang D. An epidemiologic study of tinnitus in a population in Jiangsu Province, China. *Journal of the American Academy of Audiology*. 2011;22(9):578-585. doi:10.3766/jaaa.22.9.3
- 8. Lasisi AO, Abiona T, Gureje O. Tinnitus in the elderly: Profile, correlates, and impact in the Nigerian study of ageing. *Otolaryngology Head and Neck Surgery*. 2010;143(4):510-515. doi: 10.1016/j.otohns.2010.06.817
- 9. Yetiser S, Tosun F, Satar B, Arslanhan M, Akcam T, Ozkaptan Y. The role of zinc in management of tinnitus. *Auris Nasus Larynx*. 2002;29(4):329-333. doi:10.1016/S0385-8146(02)00023-8
- GLOBAL COSTS OF UNADDRESSED HEARING LOSS AND COST-EFFECTIVENESS OF INTERVENTIONS MAKE LISTENING SAFE. Accessed May 4, 2021. www.who.int/pbd/deafness/activities/MLSMAKELISTENINGSAFEwww.who.int/pbd/deafness/activities/MLS
- 11. Stockdale D, McFerran D, Brazier P, et al. An economic evaluation of the healthcare cost of tinnitus management in the UK. *BMC health services research*. 2017;17(1):577. doi:10.1186/s12913-017-2527-2
- 12. Demographics | American Tinnitus Association. Accessed May 4, 2021. https://www.ata.org/understanding-facts/demographics
- 13. Langguth B, Kreuzer PM, Kleinjung T, de Ridder D. Tinnitus: causes and clinical management. *The Lancet Neurology*. 2013;12(9):920-930. doi:10.1016/S1474-4422(13)70160-1
- 14. Henry JA, Roberts LE, Caspary DM, Theodoroff SM, Salvi RJ. Underlying mechanisms of tinnitus: review and clinical implications. *Journal of the American Academy of Audiology*. 2014;25(1):5-22; quiz 126. doi:10.3766/jaaa.25.1.2
- 15. Drug Therapies | American Tinnitus Association. Accessed June 2, 2021. https://www.ata.org/managing-your-tinnitus/treatment-options/drug-therapies
- Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: Tinnitus. Otolaryngology -Head and Neck Surgery (United States). 2014;151(2): S1-S40. doi:10.1177/0194599814545325
- 17. Chronischer Tinnitus. Accessed May 5, 2021. http://www.awmf-leitlinien.de,
- 18. Langguth B. Treatment of tinnitus. *Current Opinion in Otolaryngology and Head and Neck Surgery*. 2015;23(5):361-368. doi:10.1097/MOO.00000000000185
- 19. Jastreboff MM. Sound therapies for tinnitus management. In:; 2007:435-440. doi:10.1016/S0079-6123(07)66042-7
- 20. Henry JA, Frederick M, Sell S, Griest S, Abrams H. Validation of a Novel Combination Hearing Aid and Tinnitus Therapy Device. *Ear & Hearing*. 2015;36(1):42-52. doi:10.1097/AUD.000000000000093
- 21. Baguley D, McFerran D, Hall D. Tinnitus. *The Lancet*. 2013;382(9904):1600-1607. doi:10.1016/S0140-6736(13)60142-7

- 22. Makar SK, Mukundan G, Gore G. Treatment of tinnitus: A scoping review. *International Tinnitus Journal*. 2017;21(2):144-156. doi:10.5935/0946-5448.20170027
- 23. Thompson DM, Hall DA, Walker D-M, Hoare DJ. Psychological Therapy for People with Tinnitus: A Scoping Review of Treatment Components. *Ear and hearing*. 2017;38(2):149-158. doi:10.1097/AUD.00000000000363
- 24. Shekhawat GS, Searchfield GD, Stinear CM. Role of Hearing Aids in Tinnitus Intervention: A Scoping Review. *Journal of the American Academy of Audiology*. 2013;24(08):747-762. doi:10.3766/jaaa.24.8.11
- 25. Tutaj L, Hoare DJ, Sereda M. Combined Amplification and Sound Generation for Tinnitus: A Scoping Review. *Ear & Hearing*. 2018;39(3):412-422. doi:10.1097/AUD.000000000000516
- 26. Elyssa Kok T, Schaette R, Shekhawat GS. Impact of tDCS and HD-tDCS on tinnitus perception: A scoping review. In:; 2021:225-244. doi: 10.1016/bs.pbr.2020.05.002
- 27. Hoare DJ, Adjamian P, Sereda M. Electrical Stimulation of the Ear, Head, Cranial Nerve, or Cortex for the Treatment of Tinnitus: A Scoping Review. *Neural Plasticity*. 2016; 2016:1-15. doi:10.1155/2016/5130503
- 28. Haider HF, Hoare DJ, Costa RFP, et al. Pathophysiology, Diagnosis and Treatment of Somatosensory Tinnitus: A Scoping Review. *Frontiers in Neuroscience*. 2017;11. doi:10.3389/fnins.2017.00207
- 29. Shekhawat GS, Stinear CM, Searchfield GD. Modulation of Perception or Emotion? A Scoping Review of Tinnitus Neuromodulation Using Transcranial Direct Current Stimulation.

 Neurorehabilitation and Neural Repair. 2015;29(9):837-846. doi:10.1177/1545968314567152
- 30. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *The BMJ*. 2021;372. doi:10.1136/bmj. n71
- 31. Folmer RL, Theodoroff SM, Casiana L, Shi Y, Griest S, Vachhani J. Repetitive Transcranial Magnetic Stimulation Treatment for Chronic Tinnitus. *JAMA Otolaryngology–Head & Neck Surgery*. 2015;141(8):716. doi:10.1001/jamaoto.2015.1219
- 32. Tyler R, Cacace A, Stocking C, et al. Vagus Nerve Stimulation Paired with Tones for the Treatment of Tinnitus: A Prospective Randomized Double-blind Controlled Pilot Study in Humans. *Scientific Reports*. 2017;7(1):11960. doi:10.1038/s41598-017-12178-w
- 33. Staecker H, Morelock M, Kramer T, Chrbolka P, Ahn JH, Meyer T. Safety of Repeated-Dose Intratympanic Injections with AM-101 in Acute Inner Ear Tinnitus. *Otolaryngology–Head and Neck Surgery*. 2017;157(3):478-487. doi:10.1177/0194599817711378
- 34. Formánek M, Migaľová P, Krulová P, et al. Combined transcranial magnetic stimulation in the treatment of chronic tinnitus. *Annals of clinical and translational neurology*. 2018;5(7):857-864. doi:10.1002/acn3.587
- 35. Sereda M, Xia J, el Refaie A, Hall DA, Hoare DJ. Sound therapy (using amplification devices and/or sound generators) for tinnitus. *Cochrane Database of Systematic Reviews*. Published online December 27, 2018. doi: 10.1002/14651858.CD013094.pub2

- 36. Londero A, Bonfils P, Lefaucheur JP. Transcranial magnetic stimulation and subjective tinnitus. A review of the literature, 2014–2016. *European Annals of Otorhinolaryngology, Head and Neck Diseases*. 2018;135(1):51-58. doi:10.1016/j.anorl.2017.12.001
- 37. Person OC, Puga ME, da Silva EM, Torloni MR. Zinc supplementation for tinnitus. *Cochrane Database of Systematic Reviews*. Published online November 23, 2016. doi: 10.1002/14651858.CD009832.pub2
- 38. Forogh B, Mirshaki Z, Raissi GR, Shirazi A, Mansoori K, Ahadi T. Repeated sessions of transcranial direct current stimulation for treatment of chronic subjective tinnitus: a pilot randomized controlled trial. *Neurological Sciences*. 2016;37(2):253-259. doi:10.1007/s10072-015-2393-9
- 39. dos Santos GM, Bento RF, de Medeiros IRT, Oiticcica J, da Silva EC, Penteado S. The Influence of Sound Generator Associated with Conventional Amplification for Tinnitus Control: Randomized Blind Clinical Trial. *Trends in Hearing*. 2014; 18:233121651454265. doi:10.1177/2331216514542657
- 40. Hoare DJ, Kowalkowski VL, Kang S, Hall DA. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. *The Laryngoscope*. 2011;121(7):1555-1564. doi:10.1002/lary.21825
- 41. Miroddi M, Bruno R, Galletti F, et al. Clinical pharmacology of melatonin in the treatment of tinnitus: a review. *European Journal of Clinical Pharmacology*. 2015;71(3):263-270. doi:10.1007/s00228-015-1805-3
- 42. Baldo P, Doree C, Molin P, McFerran D, Cecco S. Antidepressants for patients with tinnitus. *Cochrane Database of Systematic Reviews*. Published online September 12, 2012. doi: 10.1002/14651858.CD003853.pub3
- 43. Hoekstra C el, Rynja SP, van Zanten GA, Rovers MM. Anticonvulsants for tinnitus. *Cochrane Database of Systematic Reviews*. Published online July 6, 2011. doi: 10.1002/14651858.CD007960.pub2
- 44. Garin P, Gilain C, van Damme J-P, et al. Short- and long-lasting tinnitus relief induced by transcranial direct current stimulation. *Journal of neurology*. 2011;258(11):1940-1948. doi:10.1007/s00415-011-6037-6
- 45. Mennemeier M, Chelette KC, Allen S, et al. Variable changes in PET activity before and after rTMS treatment for tinnitus. *The Laryngoscope*. 2011;121(4):815-822. doi:10.1002/lary.21425
- 46. van de Heyning P, Muehlmeier G, Cox T, et al. Efficacy and Safety of AM-101 in the Treatment of Acute Inner Ear Tinnitus—A Double-Blind, Randomized, Placebo-Controlled Phase II Study. *Otology & Neurotology*. 2014;35(4):589-597. doi:10.1097/MAO.0000000000000268
- 47. von Boetticher A. Ginkgo biloba extract in the treatment of tinnitus: a systematic review. Neuropsychiatric disease and treatment. 2011; 7:441-447. doi:10.2147/NDT.S22793
- 48. Yuan T, Yadollahpour A, Salgado-Ramírez J, Robles-Camarillo D, Ortega-Palacios R. Transcranial direct current stimulation for the treatment of tinnitus: a review of clinical trials and mechanisms of action. *BMC Neuroscience*. 2018;19(1):66. doi:10.1186/s12868-018-0467-3

- 49. Zenner H-P, Delb W, Kröner-Herwig B, et al. A multidisciplinary systematic review of the treatment for chronic idiopathic tinnitus. *European Archives of Oto-Rhino-Laryngology*. 2017;274(5):2079-2091. doi:10.1007/s00405-016-4401-y
- 50. Hoare DJ, Kowalkowski VL, Kang S, Hall DA. Systematic review and meta-analyses of randomized controlled trials examining tinnitus management. *The Laryngoscope*. 2011;121(7):1555-1564. doi:10.1002/lary.21825
- 51. Fornaro M. Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management. *Neuropsychiatric Disease and Treatment*. Published online June 2010:209. doi:10.2147/NDT.S10361
- van de Heyning P, Muehlmeier G, Cox T, et al. Efficacy and safety of AM-101 in the treatment of acute inner ear tinnitus--a double-blind, randomized, placebo-controlled phase II study. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2014;35(4):589-597. doi:10.1097/MAO.00000000000000268
- 53. Vanneste S, de Ridder D. Bifrontal transcranial direct current stimulation modulates tinnitus intensity and tinnitus-distress-related brain activity. *European Journal of Neuroscience*. 2011;34(4):605-614. doi:10.1111/j.1460-9568.2011. 07778.x
- 54. Langguth B, Landgrebe M, Kleinjung T, Sand GP, Hajak G. Tinnitus and depression. *The World Journal of Biological Psychiatry*. 2011;12(7):489-500. doi:10.3109/15622975.2011.575178
- 55. Eichhammer P, Kleinjung T, Landgrebe M, Hajak G, Langguth B. TMS for treatment of chronic tinnitus neurobiological effects. In:; 2007:369-375. doi:10.1016/S0079-6123(07)66035-X
- 56. Nitsche MA, Fricke K, Henschke U, et al. Pharmacological Modulation of Cortical Excitability Shifts Induced by Transcranial Direct Current Stimulation in Humans. *The Journal of Physiology*. 2003;553(1):293-301. doi:10.1113/jphysiol.2003.049916
- 57. Shekhawat GS, Stinear CM, Searchfield GD. Modulation of Perception or Emotion? A Scoping Review of Tinnitus Neuromodulation Using Transcranial Direct Current Stimulation.

 Neurorehabilitation and Neural Repair. 2015;29(9):837-846. doi:10.1177/1545968314567152
- 58. Kim BG, Kim DY, Kim SK, Kim JM, Baek SH, Moon IS. Comparison of the outcomes of repetitive transcranial magnetic stimulation to the ipsilateral and contralateral auditory cortex in unilateral tinnitus. *Electromagnetic Biology and Medicine*. 2014;33(3):211-215. doi:10.3109/15368378.2013.801353
- 59. Tunkel DE, Bauer CA, Sun GH, et al. Clinical Practice Guideline. *Otolaryngology–Head and Neck Surgery*. 2014;151(2 suppl):S1-S40. doi:10.1177/0194599814545325
- 60. Cima RFF, Mazurek B, Haider H, et al. A multidisciplinary European guideline for tinnitus: diagnostics, assessment, and treatment. *HNO*. 2019;67(S1):10-42. doi:10.1007/s00106-019-0633-7
- 61. Sereda M, Hoare DJ, Nicholson R, Smith S, Hall DA. Consensus on Hearing Aid Candidature and Fitting for Mild Hearing Loss, With and Without Tinnitus. *Ear & Hearing*. 2015;36(4):417-429. doi:10.1097/AUD.00000000000140
- 62. Novel Tinnitus Implant System for the Treatment of Chronic Severe Tinnitus Full Text View ClinicalTrials.gov. Accessed May 31, 2021. https://clinicaltrials.gov/ct2/show/NCT03988699

- 63. de Salles AntonioAF, Soleymani T, Pezeshkian P, et al. Surgical approaches to tinnitus treatment: A review and novel approaches. *Surgical Neurology International*. 2011;2(1):154. doi:10.4103/2152-7806.86834
- 64. Experimental Therapies | American Tinnitus Association. Accessed May 31, 2021. https://www.ata.org/managing-your-tinnitus/treatment-options/experimental-therapies
- 65. Deep Brain Stimulation for Tinnitus No Study Results Posted ClinicalTrials.gov. Accessed May 31, 2021. https://clinicaltrials.gov/ct2/show/results/NCT03976908?cond=Tinnitus&draw=2&rank=2&vi ew=results
- 66. Sound therapy for tinnitus: multiflex tinnitus technology. https://starkeypro.com/pdfs/technical-papers/Tinnitus_White_Paper.pdf




Figure 1 PRISMA-ScR flow diagram(Adapted from Original PRISMA-ScR 2020 document)

^{*}PubMed (n = 838), Scopus (n = 2441), Cochrane (n = 538), Google Scholar (n = 331)

Conflicts of Interest: The authors for this paper have no conflicts of interest to declare.

Funding: This study received no funding from any agency in public, commercial or not-for-profit sectors.

Authors' Contribution:

Conceptualization, Methodology,	VC, KK
Project Administration, Supervision	KK
Resources and Data Curation	DP, PS
Analysis and Interpretation	VC, DP
Data Validation	VJ, PS
Writing original draft	VC, DP
Review and Editorial Support	JR, SM, PS, KK